Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage
- 8 Downloads
Endocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ERα)-positive breast cancer. The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ERα is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism.
Endocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues.
We found that in endocrine resistant breast cancer cells loss of ERα led to HDAC3 stabilization via decreased ERα-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ERα-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ERα expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ERα deficiency. The ERα-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples.
From our data we conclude that the ERα-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ERα loss.
KeywordsBreast cancer Loss of ERα expression HDAC3 caspase7 Endocrine resistance H3K9ac H4K16ac Epigenetic modification
This work was funded by the National Natural Science Foundation of China (Grant No.: 81572712 & 81772956 to L. Chen), the National Basic Research Program of China (973 Program) (Grant No.: 2015CB965000 to L. Chen), the Key University Science Research Project of Jiangsu Province (Grant No.: 17KJA320002 to L. Chen), grants from the Natural Science Foundation of Jiangsu Province (Grant No.: SBK2016030027 to L. Chen), the Six talent peaks project in Jiangsu Province (Grant No.: 2015-JY-002 to L. Chen), a Jiangsu Shuangchuang talent program to L. Chen, and the Priority Academic Program Development of Jiangsu Higher Education Institutions. Science and Technology Program of Nanjing, China (Grant No.: 201803052 to Z. Yu).
Conception and design: Shiyi Yu, Tao Zhu, Zhenghong Yu, Liming Chen.
Development of methodology: Liming Chen, Zhenghong Yu.
Acquisition of data (provided animals, acquired and managed patients, provided facilities): Shiyi Yu, Xue Gong, Zhifang Ma, Meng Zhang, Ling Huang, Jun zhang, Shuang Zhao, Zhenghong Yu, Liming Chen.
Analysis and interpretation of data (i.e., statistical analysis, biostatistics, computational analysis): Liming Chen, Shiyi Yu, Zhifang Ma.
Writing, review and/or revision of the manuscript: Liming Chen, Shiyi Yu.
Administrative, technical or material support (i.e., reporting or organizing data, constructing databases): Tao Zhu, Shuang Zhao, Zhenghong Yu.
Study supervision: Liming Chen.
Other (approved final version): Liming Chen.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 4.S. Moverare-Skrtic, A.E. Borjesson, H.H. Farman, K. Sjogren, S.H. Windahl, M.K. Lagerquist, A. Andersson, A. Stubelius, H. Carlsten, J.A. Gustafsson, C. Ohlsson, The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor alpha AF-2 is modified. Proc Natl Acad Sci USA. 111, 1180–1185 (2014)PubMedCrossRefPubMedCentralGoogle Scholar
- 6.R.I. Nicholson, J.M. Gee, D.L. Manning, A.E. Wakeling, M.M. Montano, B.S. Katzenellenbogen, Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 761, 148–163 (1995)PubMedCrossRefPubMedCentralGoogle Scholar
- 10.G. Arpino, S.J. Green, D.C. Allred, D. Lew, S. Martino, C.K. Osborne, R.M. Elledge, HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res 10, 5670–5676 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
- 11.J.M. Gee, J.F. Robertson, E. Gutteridge, I.O. Ellis, S.E. Pinder, M. Rubini, R.I. Nicholson, Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1), S99–S111 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
- 12.M. Dowsett, S. Johnston, L.A. Martin, J. Salter, M. Hills, S. Detre, M.C. Gutierrez, S.K. Mohsin, J. Shou, D.C. Allred, R. Schiff, C.K. Osborne, I. Smith, Growth factor signalling and response to endocrine therapy: The Royal Marsden Experience. Endocr Relat Cancer 12(Suppl 1), S113–S117 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
- 14.G. Pohl, M. Rudas, O. Dietze, S. Lax, E. Markis, R. Pirker, C.C. Zielinski, H. Hausmaninger, E. Kubista, H. Samonigg, R. Jakesz, M. Filipits, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 21, 3594–3600 (2003)PubMedCrossRefPubMedCentralGoogle Scholar
- 15.G. Perez-Tenorio, F. Berglund, A. Esguerra Merca, B. Nordenskjold, L.E. Rutqvist, L. Skoog, O. Stal, Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. J Clin Oncol 28, 1031–1042 (2006)Google Scholar
- 18.M.C. Gutierrez, S. Detre, S. Johnston, S.K. Mohsin, J. Shou, D.C. Allred, R. Schiff, C.K. Osborne, M. Dowsett, Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23, 2469–2476 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
- 21.S. Kilpinen, R. Autio, K. Ojala, K. Iljin, E. Bucher, H. Sara, T. Pisto, M. Saarela, R.I. Skotheim, M. Bjorkman, J.P. Mpindi, S. Haapa-Paananen, P. Vainio, H. Edgren, M. Wolf, J. Astola, M. Nees, S. Hautaniemi, O. Kallioniemi, Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9, R139 (2008)PubMedPubMedCentralCrossRefGoogle Scholar
- 22.R.M. Neve, K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, F. Tong, T. Speed, P.T. Spellman, S. DeVries, A. Lapuk, N.J. Wang, W.L. Kuo, J.L. Stilwell, D. Pinkel, D.G. Albertson, F.M. Waldman, F. McCormick, R.B. Dickson, M.D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J.W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527 (2006)PubMedPubMedCentralCrossRefGoogle Scholar
- 28.S.E. Elsheikh, A.R. Green, E.A. Rakha, D.G. Powe, R.A. Ahmed, H.M. Collins, D. Soria, J.M. Garibaldi, C.E. Paish, A.A. Ammar, M.J. Grainge, G.R. Ball, M.K. Abdelghany, L. Martinez-Pomares, D.M. Heery, I.O. Ellis, Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69, 3802–3809 (2009)PubMedCrossRefPubMedCentralGoogle Scholar
- 31.H. Kurokawa, A.E. Lenferink, J.F. Simpson, P.I. Pisacane, M.X. Sliwkowski, J.T. Forbes, C.L. Arteaga, Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60, 5887–5894 (2000)PubMedPubMedCentralGoogle Scholar
- 34.Y.K. Liang, Y.S. Zeng, Y.W. Xiao, Y.X. Ouyang, M. Chen, Y.C. Li, H.Y. Lin, X.L. Wei, Y.Q. Zhang, F.A. Kruyt, G.J. Zhang, MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelialemesenchymal transition, decreased ERa expression and AKT activation. Cancer Lett 386, 65–76 (2017)PubMedCrossRefPubMedCentralGoogle Scholar
- 38.J. Fabian, M. Lodrini, I. Oehme, M.C. Schier, T.M. Thole, T. Hielscher, A. Kopp-Schneider, L. Opitz, D. Capper, A. von Deimling, I. Wiegand, T. Milde, U. Mahlknecht, F. Westermann, O. Popanda, F. Roels, B. Hero, F. Berthold, M. Fischer, A.E. Kulozik, O. Witt, H.E. Deubzer, GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 74, 2604–2616 (2014)PubMedCrossRefPubMedCentralGoogle Scholar
- 39.B.M. Muller, L. Jana, A. Kasajima, A. Lehmann, J. Prinzler, J. Budczies, K.J. Winzer, M. Dietel, W. Weichert, C. Denkert, Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13, 215 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
- 40.P.N. Munster, K.T. Thurn, S. Thomas, P. Raha, M. Lacevic, A. Miller, M. Melisko, R. Ismail-Khan, H. Rugo, M. Moasser, S.E. Minton, A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104, 1828–1835 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
- 42.M. Kirschbaum, P. Frankel, L. Popplewell, J. Zain, M. Delioukina, V. Pullarkat, D. Matsuoka, B. Pulone, A.J. Rotter, I. Espinoza-Delgado, A. Nademanee, S.J. Forman, D. Gandara, E. Newman, Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29, 1198–1203 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
- 43.D.R. McIlwain, T. Berger, T.W. Mak, Caspase functions in cell death and disease. CSH Perspect Biol 5, a008656 (2013)Google Scholar
- 51.G. Vidali, L.C. Boffa, E.M. Bradbury, V.G. Allfrey, Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 75, 2239–2243 (1978)PubMedCrossRefPubMedCentralGoogle Scholar